Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study

What Was Tested

Researchers studied Orforglipron (Foundayo, non-peptide) in this randomized controlled trial publication.

Orforglipron, an oral, non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist, is in development for type 2 diabetes and obesity.

Who Took Part

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

In this 26-week, phase 2, double-blind, randomised, multicentre study, participants were recruited from 45 centres (private clinics, hospitals, and research centers) in the USA, Hungary, Poland, and Slovakia.

Participants were masked to the study drug, dulaglutide, and placebo.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and multicenter study.

The participants were allocated by chance, so the Orforglipron (Foundayo, non-peptide) group and the comparison group should start out alike.

As a double-blind Orforglipron (Foundayo, non-peptide) study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Orforglipron (Foundayo, non-peptide) could be set against what happens without it.

Running at several centres spread the Orforglipron (Foundayo, non-peptide) study over different clinics and patient groups.

This trial is registered at ClinicalTrials.gov (NCT05048719) and is completed.

What Was Measured

Topics PubMed links to this paper include Diabetes Mellitus, Type 2, Hypoglycemic Agents, Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptides and Hypoglycemia.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Orforglipron (Foundayo, non-peptide).

The abstract goes on to report its results in about 12 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2023 (Lancet (London, England)), a journal based in England.

More context: the Orforglipron (Foundayo, non-peptide) compound page, all human trials.